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Abstract
Introduction: Graves’ disease and myasthenia gravis are both auto-immune diseases and the
coexistence of these two diseases is rare but well recognized. Myasthenia gravis is more frequent in
patients with thyroid disease.
Case presentation: Here we present a case of 28-year-old male patient having Auto-immune
thyroid disease (Graves’ disease) with concomitant myasthenia gravis.
Conclusion: In conclusion, we report that the coexistence of Myasthenia Gravis with Autoimmune
thyroid disease might have prognostic relevance and occurs in a subgroup of myasthenia gravis
patients with a mild form of the disease.
Introduction
Robert Graves’ disease, although first described by Parry
in 1825 [1], is best known as Graves’ disease and is
characterized by diffuse goiter (Thyrotoxicosis), infiltrative
orbitopathy & ophthalmopathy and occasionally infiltra-
tive dermopathy. It occurs in up to 2% of women and 0.2%
in men. The disorder rarely begins before adolescence and
typically occurs between 20 and 50 years of age and rarely it
occurs in elderly as well. It is an autoimmune disorder with
autoantibodies directed against the TSHR (TSHR Abs) and
behave as thyroid-stimulating antibodies [2,3]. Pathologi-
cally Graves’ disease, is characterized by a non-homoge-
neous lymphocytic (T-cells: Th1 and Th2 types along
with CD25+ regulatory T cells; while B-cell germinal centers
are much less common) infiltration with an absence of
follicular destruction [4]. Clinically it is characterized by
hyperactivity, irritability, dysphoria, heat intolerance, sweat-
ing, palpitations, fatigue, weakness, weight loss despite
increased appetite, diarrhea, polyuria, oligomenorrhea, loss
of libido, tachycardia, atrial fibrillation, tremors, goiter,
warm, moist skin, muscle weakness, proximal myopathy,
lid retraction/lag, gynecomastia [5]. Other auto-immune
disorders occurring in association with Graves’ disease
include Acquired hypokalemic periodic paralysis, Myasthe-
nia gravis, Insulin-dependent diabetes mellitus, Pernicious
anemia, Adrenal atrophy, Sjogren’s syndrome, Lupus
erythematosus, Rheumatoid arthritis and Idiopathic
thrombocytopenic purpura, vitiligo.
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Case presentation
A 28-year-old Indian male, with Indoaryan ethnicity non-
smoker, non-alcoholic patient, laborer by occupation
presented to hospital with a history of gradually increasing
painful swelling in the neck of 3 months duration
associated with difficulty in swallowing and palpitations.
It was not associated with hoarseness of voice, difficulty in
breathing. Patient also complained of low grade fever of
3 months duration, continuous, associated with chills but
no rigors or any diurnal variations. There was also history
of generalized weakness, diplopia on downward gaze,
drooping of eyelids on both sides. Patient had no such
complaint in past or no such history was found in family
or first degree relatives. On examination patient was
conscious, oriented, with nasal twang speech. Look was
lethargic and had proptosis and ptosis. Large thyroid
swelling was visible, bilaterally symmetrical and tender,
smooth, firm in consistency, non-fluctuant, with audible
bruit present. B.P-100/60 mmHg, Pulse- 98/min, Temp-
100 0F and respiratory rate of 18/min. Examination also
revealed bilateral weakness of superior recti, inferior
oblique, lateral recti and left medial rectus.
Investigations revealed Hb-12 g/dl, TLC-9,000/cmm, DLC-
N68 E3 L27M2 B0, Platelets - 2.25 lacs/cmm, ESR - 35mm,
P.B.F - Normocytic normochromic picture, Urea-13 mg/dL,
Bl. Glucose (R)- 92 mg/dL, Sr. Creatinine-0.5 mg/dL, Sr.
total protein- 6.9 g/dL, Sr. albumin- 3.1, SGOT- 56 U/L,
SGPT -20 U/L, ALP- 116 U/L, Sr.Ca++= 1.01 mmol/L,
Phosphate-4.0 mg/dl, S.sodium-136meq/l, Sr. K+-2.9 meq/l,
Chest X-ray-Normal, X-ray neck- soft tissue swelling
anterior to trachea, routine urine exam- normal, ECG- PR
interval prolonged, flattened T waves, TSH- 0.005 µIU/ml,
Free T4- 6.89 ng/dL, Free T3- 16.19 pg/ml. FNAC thyroid-
thyroid follicular cells, colloid, Hurthle cells and lympho-
cytes (features suggestive of Hashimoto’s thyroiditis),
and Neostigmine test for myasthenia gravis- Positive
(Figures 1 and 2).
In addition to Neomercazole 10 mg three times daily,
Pyridostigmine 30 mg three times daily was added for the
treatment of ptosis and increased to 60 mg t.i.d., with
patient showing dramatic improvement both in symp-
toms and signs after the start of therapy.
Discussion
Patients with myasthenia gravis may have coexisting AITD,
which include Hashimoto’s disease Type 2A and Graves’
disease Type 3A. Epidemiological studies show that AITD
occur in approximately 5-10% of patients with MG,
whereas MG is reported in a fairly low frequency (0.2%)
of patients with AITD. The clinical presentation of MG
associated with AITD is frequently restricted to eye
muscles. The reason for the association of AITD with
ocular MG is unknown, but several hypotheses can be
considered. First, ocular MG and generalized MG might
actually represent separate diseases with different spectra
of associated conditions. Second, an immunological cross-
reactivity against epitopes or auto-antigens shared by the
thyroid and the eye muscles might be the basis of this
association. A third explanation for the higher frequency
of ocular MG in AITD could be that these disorders have a
common genetic background [6]. In three-quarters of
patients with both conditions, thyrotoxic symptoms occur
before or concurrently with those of myasthenia [7]. Our
patient had thyrotoxicosis symptoms 2 months before his
ptosis developed. The ocular changes in Graves’ disease
may include exophthalmos, periorbital edema, lid lag,
chemosis and ophthalmoplegia. The extraocular muscles
most commonly involved in Graves’ disease are the
superior and lateral recti [8]. Two-thirds of the patients
with both disorders show improvement in myasthenia
gravis after treatment of thyroid disease [8].
Conclusion
In conclusion, we report that the coexistence of MG with
AITD might have prognostic relevance and occurs in a
subgroup of MG patients with a mild form of the disease.
It should be remembered that, ptosis is not an expected
symptom in thyroid ophthalmopathy. If ptosis or paresis
of the orbicularis oculi muscle develops in a patient with
thyroid ophthalmopathy, coincidence of myasthenia
gravis should be considered.
Consent
Written informed consent was obtained from the patient
for publication of this report and accompanying images.
Figure 1. Showing ptosis before neostigmine test.
Figure 2. Showing improvement in ptosis after neostigmine
test.
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A copy of written consent is available for review by
Editor-in-Chief of this journal.
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